Effects of dicentrine, a novel alpha 1-adrenoceptor antagonist, on human hyperplastic prostates.
The effects of dicentrine, an alpha 1-adrenoceptor antagonist, on human hyperplastic prostates were investigated by radioligand binding and in vitro isometric tension experiments. In human hyperplastic prostates, alpha 1-adrenoceptors were characterized by a binding assay using [3H]prazosin as a radioligand. Specific [3H]prazosin binding was saturable and of high affinity (Kd = 0.2 +/- 0.02 nM) with a maximal number of binding sites (Bmax = 55.2 +/- 3.2 fmol/mg protein). alpha-Adrenoceptor antagonists competed with [3H]prazosin for binding in the order: dicentrine > phentolamine > rauwolscine. Norepinephrine (0.3-100 microM) or phenylephrine (1-300 microM) produced gradual contractions of human hyperplastic prostates. The concentration-response curve of norepinephrine or phenylephrine was shifted in parallel to the right by dicentrine, consistent with a competitive blockade. The pA2 values of dicentrine against norepinephrine and phenylephrine were 8.04 +/- 0.09 and 8.33 +/- 0.11, respectively. These experiments were conducted to confirm that there was no interaction between alpha 1- and alpha 2-adrenoceptors in the tissue. Rauwolscine (1 microM) caused 1.7-fold, while dicentrine (0.1 microM) caused 15.8-fold shift of norepinephrine-induced contraction of human hyperplastic prostates. Combination of rauwolscine with dicentrine caused 17.8-fold shift of norepinephrine-induced prostatic tissue contraction. The contractile response to transmural field stimulation was abolished by pretreatment with tetrodotoxin, and suppressed concentration dependently by dicentrine or prazosin, whereas rauwolscine had little effect. It is concluded that dicentrine inhibits human hyperplastic prostate contractions in response to exogenous and endogenous adrenergic stimulation. Dicentrine may thus hold potential to relieve bladder outlet obstruction caused by benign prostatic hyperplasia via alpha 1-adrenoceptor blockade.
Yu
S M
SM
Department of Pharmacology, Chang Gung Medical College, Kwei-San, Tao-Yuan, Taiwan.
Ko
F N
FN
Chueh
S C
SC
Chen
J
J
Chen
S C
SC
Chen
C C
CC
Teng
C M
CM
D000317:Adrenergic alpha-Antagonists / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D001060:Aporphines / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001665:Binding Sites; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology; D010646:Phentolamine / Q000378:metabolism; D011224:Prazosin / Q000378:metabolism; D011467:Prostate / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D011869:Radioligand Assay; D015016:Yohimbine / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D001060:Aporphines; D015016:Yohimbine; C067342:dicentrine; D009638:Norepinephrine; D011224:Prazosin; D010646:Phentolamine